Corcept Therapeutics (CORT) Current Deferred Revenue (2012 - 2015)

Corcept Therapeutics has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $158000.0 for Q4 2015.

• Current Deferred Revenue for Q4 2015 came in at $158000.0, up 378.79% year-over-year; the trailing twelve-month figure through Dec 2015 was $158000.0 (up 378.79% YoY), and the FY2015 annual result was $158000.0, up 378.79% from the prior year.
• Current Deferred Revenue came in at $158000.0 for Q4 2015 at Corcept Therapeutics, up from $79000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $158000.0 in Q4 2015 to a low of $16000.0 in Q4 2012.
• The 4-year median for Current Deferred Revenue is $37000.0 (2013), against an average of $49400.0.
• Across the five-year window, Current Deferred Revenue slumped 61.84% in 2014 and jumped 378.79% in 2015, its largest moves.
• Corcept Therapeutics' Current Deferred Revenue stood at $16000.0 in 2012, then surged by 56.25% to $25000.0 in 2013, then jumped by 32.0% to $33000.0 in 2014, then surged by 378.79% to $158000.0 in 2015.
• The last three Current Deferred Revenue figures came in at $158000.0 (Q4 2015), $79000.0 (Q3 2015), and $37000.0 (Q2 2015), per Business Quant data.